Insight Molecular Diagnostics Nears FDA Submission with GraftAssureDx Milestones

Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) has made significant progress in advancing its GraftAssureDx test kit toward FDA submission by completing critical milestones. Key clinical trials were successfully concluded at prominent medical centres, including Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health. These achievements advance iMDx’s aim to revolutionise the $2 billion transplant rejection testing market, promising enhanced access and localised testing for kidney transplant patients.

Based in Nashville, Tennessee, Insight Molecular Diagnostics is poised to deliver a cutting-edge molecular diagnostic test for the healthcare industry. The GraftAssureDx test kit, intended to improve organ health testing accessibility for kidney transplant patients, represents a significant advancement in regulated transplant rejection diagnostics. The company’s recent completion of a three-site reproducibility study, combined with sufficient clinical sample acquisition, signals readiness for an in vitro diagnostic De Novo submission to the FDA. Additionally, receiving ISO 13485 certification strengthens iMDx’s foothold for potential U.K. and E.U. regulatory submissions, further broadening its market reach.

With these recent milestones, Insight Molecular Diagnostics is on the brink of achieving a major breakthrough in kidney transplant diagnostics. As the company wraps up the remaining internal studies, its promising GraftAssureDx kit is set to transform the industry landscape by enhancing testing efficiency and accessibility. Once fully approved, this innovation is expected to benefit thousands of patients worldwide, underscoring iMDx’s leadership in molecular diagnostics.